



News Release

Revenue growth at 7.44%, R&D spent at 24.53% of Revenue

17 Product Patents obtained during the qtr globally

Establishes Second CNS Drug Discovery Collaboration with Lilly

HYDERABAD, INDIA (Apr' 26, 2008) – SUVEN LIFE Science's Board of Directors meeting held today in Hyderabad announced the results that the revenues are at Rs. 12304 lacs for the year ended Mar' 2008 compared to Rs. 11451 lacs for the corresponding previous year. PAT stood at Rs. 826 lacs compared to Rs. 1131 for the corresponding previous year, a decline of 27%.

The segmental revenue for the year from DDDSS increased by 140 % to Rs.2768 lacs from Rs.1155 lacs. However, there is reduction in CRAMS revenue for the year from Rs. 10151 lacs to Rs. 9227 lacs, by 9%.

For the 4th quarter ending Mar' 2008, the revenues stood at Rs.3516 lacs compared to the corresponding previous quarter of Rs.2866 lacs. The PAT stood at Rs.194 lacs compared to Rs.291 lacs for the corresponding previous quarter.

Overall for the year the main factor which influenced the deficit in revenues and profits is the Rupee appreciation by Rs.744 lacs while comparing with previous year figures.

Suven's major thrust on innovative R&D in Drug Discovery continues with a total expenditure (revenue & capital) of Rs 3018 lacs recording about 24.53% of revenue for the year.

During the Quarter Suven has obtained 4 US patents, 3 EU patents, 4 Indian patents, 2 Russian patents, 2 Korean patents and 2 Mexican patents totaling 17 global product patents. The granted claims of the patent include the class of selective Serotonin receptor affinity compounds discovered by Suven and are being developed as therapeutic agents. The compounds are useful in the treatment of neurodegenerative disorders like Alzheimer's, Parkinson, Schizophrenia and Huntington's.

During the Quarter Suven's entered into second CNS collaborative research partnership program with Lilly. Under the terms of the collaboration agreement, Suven will receive research funding as well as potential discovery and development milestone payments in the range of \$19 million to \$23 million per candidate, and potential royalties on net sales of any products that may be successfully commercialized from the collaboration.

During the Quarter Suven's CRO division ACT entered into strategic alliance for CRO business with VPSCRO, China

Suven Life Sciences is a Hyderabad based Biopharmaceutical Company; a Collaborative Research Partner (CRP) since 2006 in Drug Discovery for global pharma major is a pioneer in Contract Research and Manufacturing Services (CRAMS) since 1995 and Drug Discovery Development Support Services (DDDSS) since 2005. Suven has been involved in development of path breaking technologies for global pharma companies for more than a decade.

A focused provider of DDDSS for development of New Chemical Entities to life sciences companies, Suven's commitment to protection of intellectual property, maximization of return on R&D investments for collaborative research partners, ability to offer full spectrum of services from discovery to market launch and provide technologies and expertise in different therapeutic areas. Suven has R&D strength of more than 300 professionals with the state of the art infrastructure for Drug Discovery and development activities and the front end project management services from New Jersey, USA. For more information on Suven, please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;